Type 2 & other diabetes

GIP contributes to postprandial regulation of splanchnic blood supply in humans with type 2 diabetes: a randomised, single-blinded, placebo-controlled, crossover study

DiabetologiaPublished Randomised controlled trial

Primary result · Mean blood flow in arteria mesenterica superiorResult — go to the resultDifference 15 % 95% CI −2 to 32

Authors' conclusion

Endogenous GIP contributes to postprandially increased splanchnic blood flow in people with type 2 diabetes.

Study context

Population
Participants with T2D, age 20–80 years, BMI 20–35 kg/m², HbA1c >48 mmol/mol and <75 mmol/mol; Rigshospitalet, Copenhagencrossover, 4 occasions
Participants
10 participants
Comparison
Oral glucose + i.v. GIPNH2 vs oral glucose + i.v. saline
Primary endpoint
Changes in blood flow in arteria mesenterica superior (phase-contrast MRI) during oral glucose with or without GIP receptor antagonist infusion
Methodological detailscrossover, single-blinded, placebo-controlled, single-centre, Participants unaware of allocation, investigators aware; randomisation via random.org
  • Crossover
  • Single-blinded
  • Placebo-controlled
  • Single-centre
  • Participants unaware of allocation, investigators aware; randomisation via random.org

Primary result

Mean blood flow in arteria mesenterica superior

Difference

15 %

95% CI −2 to 32

P = 0.012

Glucose + GIP(3-30)NH2vs Glucose + saline
difference 15 % (95% CI −2 to 32); P = 0.012

As reported in the abstract

Oral glucose alone increased mean blood flow in arteria mesenterica superior
57% (95% CI 26, 88)

Further findings

Insulin secretion, C-peptide, C-peptide/glucose ratio, glucagon, plasma glucose

GIP receptor antagonist during oral glucose lowered insulin secretion, C-peptide and C-peptide/glucose ratio vs saline; glucagon and plasma glucose unaffected

Oral water

Oral water did not affect any outcomes

Original publication

GIP contributes to postprandial regulation of splanchnic blood supply in humans with type 2 diabetes: a randomised, single-blinded, placebo-controlled, crossover study. Diabetologia. Published 2 July 2026. doi:10.1007/s00125-026-06788-1

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.